** Shares of Hims & Hers Health Inc surged to a record high, last up 19% and extending recent gains after raising its annual rev forecast last week
** HIMS reached as high as $29.68 during session; last at $28.00
** The telehealth firm on Nov. 5 raised its full-yr rev forecast to $1.46-$1.47 bln from $1.37-$1.40 bln and said it would add a generic version of Novo Nordisk's diabetes and weight loss drug, liraglutide, to its platform in 2025
** Soaring demand for weight-loss drugs made by Novo and Eli Lilly has led to shortages that allow them to be produced under U.S. regulations
** HIMS now up 213% YTD vs S&P 500's 26% increase
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。